In the late 1990s, we routinely performed cervical surgical excision for all cervical intra-epithelial neoplasia (CIN) diagnoses, including CIN1. In that decade, we believed there was a steady progression from CIN1 to CIN2, CIN3, and ultimately cancer. Fast-forward more than 20 years and we now understand that the vast majority of CIN1 regresses without intervention, perhaps in part due to immune stimulation by the biopsy itself. This understanding has resulted in fewer cervical excisions, ultimately benefitting patients as well as saving healthcare dollars. It has also informed the shift in recommended terminology from the three-tiered CIN system for Pap tests to the binary system of low-grade (LSIL) versus highgrade squamous intra-epithelial lesion (HSIL) (Darragh et al. Arch Pathol Lab Med 2012; 136:1266-97) .
Despite this shift, inclusion of the CIN2 category has persisted. This is in part because, although functionally lumped together under the HSIL umbrella, CIN2 and CIN3 are not equivalent. While we know that untreated CIN3 will progress to carcinoma in a significant portion of women, the biological potential of CIN2 is less certain. This ambiguity is attributable in part to the challenges around CIN2 diagnosis. In one study of over 1000 samples in which slides were reviewed by two independent pathologists, CIN2 had the lowest agreement, with fewer than half confirmed by panel members (Dalla Palma et al. Am J Clin Pathol 2009; 132:125-32 ). An even larger study of over 20 000 biopsies compared an 'expert' review to community diagnosis and found that panel agreement with community diagnosis was only 38% for CIN2 (Stoler et al. Am J Surg Pathol 2015; 39:729-36) . These and other studies suggest that CIN2 is the least reproducible of the CIN diagnoses. Importantly, p16 immunostaining has shown value in improving inter-observer variability in CIN2 and can help identify the CIN2 cases more likely to progress (Miralpeix et al. Given the poor inter-observer variability of a CIN2 diagnosis, it is not entirely surprising that the current paper found that a large proportion of these lesions regressed (Skorstengaard, BJOG 2020; https://doi.org/10.1111 / 1471 ). Importantly, the study lacked a pathology review; therefore, it is unclear how much misclassification of CIN1 as CIN2 contributed to the high regression rate. Nonetheless, the results provide further evidence that a CIN2 diagnosis should not be treated as equivalent to CIN3 in the routine practice setting.
The goal of Pap test screening and colposcopically directed biopsies with subsequent surgical treatment is to prevent the development of invasive cervical cancer. However, our patients are not well served by cervical excisions that are unnecessary, and many clinicians around the world feel obligated to act on a CIN2 diagnosis. Determining the best way forward is challenging. Managerially lumping CIN2 alongside CIN3 in the HSIL category has clearly resulted in overtreatment for some women, yet shifting CIN2 into the LSIL camp could result in dangerously conservative management in others. Data suggest that our patients are better served by a more nuanced approach to CIN2 that includes diagnostic caution with liberal utilisation of p16 immunohistochemistry and clinical incorporation of the patient's individual situation including age, desire for future pregnancy, and presence or absence of persistent dysplasia. 
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